Keytruda sales expected to surpass 300 billion won
By Nho, Byung Chul | translator Kim, Jung-Ju
24.02.15 05:50:45
가나다라
0
Yervoy generated sales of 10.6 billion in 3Q last year, despite being the first approved immune checkpoint
Tecentriq 14.9 billion won → 70.7 billion won in four year, showing 374% growth in performance
▲(Photos, clockwise from upper left) Keytruda, Yerboy, Opdivo, and Tecentriq.
Keytruda holds a blockbuster position in the immune checkpoint inhibitors sector, with analysts expecting its sales to surpass 300 billion won.
According to the distribution performance report, MSD’s Keytruda recorded 289.8 billion won, leading its sector. It was followed by BMS-Ono’s Opdivo, which accumulated 99.3 billion won up to 3Q 2023.
In the same period, Roche Korea’s Tecentriq, AstraZeneca’s Imfinzi, BMS’s Yervoy, and Merck’s Bavencio reached sales of 70.7 billion won, 55.5 billion won, 10.6 billion won, and 2.1 billion won, respectively.
The sales of Keytruda and Tecentriq have shown remarkable growth.
Keytruda demonstrated a 132% sa
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)